Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CareRxFRA:29C1 66 ROC (Joel Greenblatt) % is 15.11% as of Jun. 2026. GuruFocus rates FRA:29C1 with a GF Score™ of 66/100 and a GF Value™ of €1.37. The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, CareRx ranks better than 61.83% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CareRx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 15.11%.
The historical rank and industry rank for CareRx's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:29C1'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -123.71 Med: -19.14 Max: 20.15
Current: 20.15
During the past 13 years, CareRx's highest ROC (Joel Greenblatt) % was 20.15%. The lowest was -123.71%. And the median was -19.14%.
FRA:29C1's ROC (Joel Greenblatt) % is ranked better than 61.83% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 12.515
vs FRA:29C1: 20.15
CareRx's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for CareRx's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:29C1 vs HCA, THC, DVA: ROC (Joel Greenblatt) % Comparison
For the Medical Care Facilities subindustry, CareRx's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CareRx ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, CareRx's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CareRx's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 15.11% mean?
CareRx (FRA:29C1) has a ROC (Joel Greenblatt) % of 15.11% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CareRx and its competitors. According to the industry distribution chart, CareRx ranks #255 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 38.2%.
Is CareRx's ROC (Joel Greenblatt) % too high?
CareRx's current ROC (Joel Greenblatt) % is 15.11%. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.52. CareRx's value of 15.11% is 20.7% above this industry median. Based on the distribution chart, CareRx ranks #255 out of 668 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, CareRx has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does CareRx's ROC (Joel Greenblatt) % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, CareRx ranks #255 out of 668 companies for ROC (Joel Greenblatt) %. This puts CareRx in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 12.52. CareRx's value of 15.11% is 20.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.52, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CareRx's current ROC (Joel Greenblatt) % of 15.11% is 20.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CareRx and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CareRx's current ROC (Joel Greenblatt) % is 15.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareRx stock overvalued right now?
CareRx (FRA:29C1) has a current ROC (Joel Greenblatt) % of 15.11%. The stock's GF Value™ is €1.37, compared to a current price of €2.04 — trading 48.9% above its estimated fair value. The current ROC (Joel Greenblatt) % is 15.11% and 20.7% above the Healthcare Providers & Services industry median of 12.52. CareRx's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CareRx (FRA:29C1), the current ROC (Joel Greenblatt) % is 15.11% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CareRx (FRA:29C1) Overvalued in 2026?
Based on GuruFocus' analysis, CareRx stock appears to be overvalued.
The current stock price of €2.04 is trading 48.9% above its estimated GF Value™ of €1.37.
Key valuation signals for FRA:29C1:
ROC (Joel Greenblatt) %: 15.11%
GF Value™: €1.37 vs. price of €2.04 (48.9% above fair value)
Industry Position: 20.7% above the Healthcare Providers & Services median (#255 of 668)
No single metric tells the full story. See the FRA:29C1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CareRx Corp is a provider of specialty pharmacy services to seniors. The company is a national organization with a large network of pharmacy fulfilment centers strategically located across the country. This allows it to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. It takes an active role in working with its home operator partners to promote resident health, staff education and medication system quality and efficiency. The Company has one reportable segment which consists of the Company-owned and operated institutional pharmacy business. Geographically it derives revenue from the sales of goods and capitated service fees in Ontario and Western Canada.
66GF Score
Get the complete analysis for FRA:29C1
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:29C1 has been successfully added to your 
